ТЕНЕКТЕПЛАЗА: НОВЫЕ ВОЗМОЖНОСТИ СИСТЕМНОЙ ТРОМБОЛИТИЧЕСКОЙ ТЕРАПИИ ПРИ ОСТРОМ КОРОНАРНОМ СИНДРОМЕ С ПОДЪЕМОМ СЕГМЕНТА ST
https://doi.org/10.20996/1819-6446-2010-6-6-837-842
Аннотация
Обсуждают возможности и преимущества применения нового тканевого активатора плазминогена — тенектеплазы у пациентов с острым коронарным синдромом (ОКС) с подъемом сегмента ST. Основным фактором ее успешного применения является время. Подробно освещены сравнительные исследования тенектеплазы с другим тканевым активатором плазминогена. Сравнивают эффективность тромболитической терапии и чрескожных коронарных вмешательств. Приводят данные многоцентровых рандомизированных клинических исследований о возможности сочетания тенектеплазы с эноксапарином и нефракционированным гепарином в стационаре. Представлены данные по безопасности применения тенектеплазы при лечении ОКС с подъемом сегмента ST.
Об авторах
Н. А. Новикова
Первый Московский Государственный Медицинский Университет им. И.М. Сеченова
Россия
Россия
д.м.н., профессор кафедры профилактической и неотложной кардиологии ФППОВ
119992, Москва, Трубецкая ул., д. 8, стр. 2
А. Е. Удовиченко
Первый Московский Государственный Медицинский Университет им. И.М. Сеченова
Россия
Россия
к.м.н., врач анестезиолог- реаниматолог отделения реанимации и интенсивной терапии Первой Университетской клинической больницы
119992, Москва, Трубецкая ул., д. 8, стр. 2
Список литературы
1. ECS Guidelines: Management of acute myocardial infarction in patients presenting with persistent STsegment elevation. Eur Heart J 2008; 29(23): 2909-2946
2. Boersma E., Maas A.C., Deckers J.W., Simoons M.L. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348(9030): 771-775
3. Tsikouris J.P., Tsikouris A.P. A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy 2001;21:207–217.
4. Vakili B.A., Kaplan R., Brown D.L. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. Circulation 2001; 104: 2171–2176.
5. Collen D., Stassen J.M., Yasuda T. et al. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994;72:98–104.
6. Cannon C.P., McCabe C.H., Gibson C.M. et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351–356.
7. Cannon C.P., Gibson C.M., McCabe C.H. et al. TNK-tissue plasminogen activator compared with frontloaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98:2805–2814.
8. Antman E.M., Hand M., Armstrong P.W. et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296–329.
9. Van de Werf F., Cannon C.P., Luyten A. et al. Safety assessment of single-bolus administration of TNK tissue-plasminogen activatorin acute myocardial infarction:theASSENT-1trial. TheASSENT-1Investigators. Am Heart J 1999;137:786–91.
10. Giugliano R.P., McCabe C.H., Antman E.M. et al. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J 2001;141:742–750.
11. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial.Assessment ofthe Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999;354:716–722.
12. Van de Werf F., Barron H.V., Armstrong P.W. et al. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin- specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001;22:2253–2261.
13. Melandri G., Vagnarelli F., Calabrese D. et al. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Vascular Health and Risk Management 2009: 5; 249-256
14. Sinnaeve P.A., Alexander J.B., Belmans A.C. et al. One-year follow-up of the ASSENT-2 trial: A double-blind,randomized comparison of single- bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST- elevation acute myocardial infarction. Am Heart J 2003;146:27–32.
15. Sabatine M.S., Cannon C.P., Gibson C.M. et al; the CLARITY-TIMI 28 Investigators. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med 2005;352:1179–1189.
16. Antman E.M., Morrow D.A., McCabe C.H. et al; the ExTRACT-TIMI 25 Investigators. Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction. N Engl J Med 2006;354:1477–1488.
17. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605–613.
18. Antman E.M., Louwerenburg H.W., Baars H.F. et al., the ENTIRE-TIMI 23 Investigators. Enoxaparin asAdjunctiveAntithrombin Therapy for ST-ElevationMyocardial Infarction: Results ofthe ENTIRE- Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642–1649.
19. Kaul P., Armstrong P.W., Cowper P.A. et al. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. Am Heart J 2005;149:637–644.
20. Giugliano R.P., Roe M.T., Harrington R.A. et al. Combination reperfusion therapy with eptifibatide and reduced dose tenecteplase for ST-elevation myocardial infarction: Results ofthe integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase IIAngiographic urial.JAm Coll Cardiol 2003;41:1251– 1260.
21. Topol E.J. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905–1914.
22. Wallentin L., Goldstein P., Armstrong P.W. et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003;108:135–142.
23. Armstrong P.W., Chang W.C., Wallentin L. et al. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. CMAJ 2006;174:1421–1426.
24. Le May M.R., Wells G.A., Labinaz M. et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). J Am Coll Cardiol 2005;46:417–424.
25. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006;367:569–578.
26. Armstrong P.W., WEST Steering Committee. A comparison of pharma- cologic therapy with/without timely coronary intervention vs primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J 2006;27:1530–1538.
27. Fernandez-Aviles F., Alonso J.J., Pena G. et al. Primary angioplasty vs early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J 2007;28:949–960.
28. Boehmer E., Hoffmann P., Abdelnoor M., Arnesen H., Halvorsen S. Efficacy and Safety of Immediate Angioplasty Versus Ischemia-Guided Management After Thrombolysis in Acute Myocardial Infarction in Areas With Very Long Transfer Distances. Results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-Elevation Myocardial Infarction) J Am Coll Cardiol 2010; 55:102-110
29. Goodman S.G., Menon V., Cannon C.P. et al. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:708S–775S.
30. Kalla K., Christ G., Karnik R. et al. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry). Circulation 2006;113:2398–2405.
31. Ting H.H., Rihal C.S., Gersh B.J. et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 2007;116:729–736.
32. Danchin N., Coste P., Ferrieres J. et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment- elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation 2008;118:268–276.
Рецензия
Для цитирования:
Новикова Н.А., Удовиченко А.Е. ТЕНЕКТЕПЛАЗА: НОВЫЕ ВОЗМОЖНОСТИ СИСТЕМНОЙ ТРОМБОЛИТИЧЕСКОЙ ТЕРАПИИ ПРИ ОСТРОМ КОРОНАРНОМ СИНДРОМЕ С ПОДЪЕМОМ СЕГМЕНТА ST. Рациональная Фармакотерапия в Кардиологии. 2010;6(6):837-842. https://doi.org/10.20996/1819-6446-2010-6-6-837-842
For citation:
Novikova N.A., Udovichenko A.E. TENEKTEPLASE: NEW POSSIBILITIES FOR SYSTEMIC THROMBOLYTIC THERAPY OF ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION. Rational Pharmacotherapy in Cardiology. 2010;6(6):837-842. (In Russ.) https://doi.org/10.20996/1819-6446-2010-6-6-837-842
Просмотров:
805
.jpg)
Послать статью по эл. почте 